文献速递类风湿关节炎

T细胞亚群生物标志物贯穿类风湿关节炎疾病连续体:从临床效用到日常实践

T-cell subset biomarkers across the rheumatoid arthritis disease continuum: from clinical utility to adoption in daily practice.
PubMed 文献 · Rheumatology (Oxford) · 2026-01-01

该研究探讨CD4+ T细胞亚群(naive、Treg、IRC)在类风湿关节炎从高危到药物诱导缓解全过程中的动态变化。流式细胞术数据显示,naive/IRC数据可提高RA分类准确性(尤其ACPA阴性者),naive T细胞频率可预测甲氨蝶呤反应,不同作用机制药物对T细胞亚群影响不同。

要点

  • naive/IRC数据提高RA分类准确性,尤其ACPA阴性患者
  • naive T细胞频率可预测未经治疗RA的甲氨蝶呤反应
  • TNF抑制剂与csDMARDs对T细胞亚群的动态影响不同

核心结论

  • T细胞亚群测量独立于现有生物标志物,验证了其作为RA生物标志物的潜力
  • 不同作用机制药物对naive、IRC、Treg三个T细胞亚群的影响存在差异
  • 早期RA中预测TNF抑制剂反应的生物标志物仍存在未满足需求

研究设计与样本

  • 采用流式细胞术获取CD4+ T细胞亚群(naive、Treg、IRC)生物标志物数据
  • 多组比较使用ANOVA检验(Bonferroni校正)
  • 纵向分析覆盖从RA高危个体到药物诱导缓解的疾病连续体

主要发现

  • RA高危个体中,IRC频率在临床滑膜炎发作前升高,进展者naive T细胞频率降低而非进展者升高
  • 晚发型RA(>60岁 vs <59岁)呈现独特的T细胞生物标志物特征
  • 未经治疗RA中,naive T细胞频率对甲氨蝶呤反应的预测价值得到确认
  • 甲氨蝶呤治疗患者中,naive T细胞仅在6至12个月间且仅在缓解时增加,IRC和Treg无一致变化
  • TNF抑制剂治疗患者中,naive T细胞频率增加与反应无关,持续IRC降低和Treg升高见于缓解者

关键数值与推荐

  • 晚发型RA定义为>60岁,对照组为<59岁
  • 甲氨蝶呤治疗患者naive T细胞增加仅见于6至12个月间且仅当处于缓解
  • 稳定临床缓解后,csDMARDs治疗者仅naive频率随缓解时间增加,TNF抑制剂诱导缓解者仅Treg随时间增加

临床怎么用

  • naive/IRC数据可用于提高RA分类准确性,尤其对ACPA阴性患者
  • naive T细胞频率可用于预测未经治疗RA患者对甲氨蝶呤的反应
  • 监测T细胞亚群动态有助于理解不同作用机制药物的免疫效应差异

局限性

  • 早期RA中预测TNF抑制剂反应的生物标志物仍属未满足需求
  • IRC和Treg在甲氨蝶呤治疗中未见一致变化

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The biomarker potential of CD4+ T-cell subsets [naive, regulatory (Treg), inflammation-related cells (IRC)] in patients with rheumatoid arthritis (RA) has been described.This article investigates the dynamic changes in these biomarkers across the RA disease continuum from at-risk to drug-induced remission. METHODS: T-cell subset biomarker data were acquired using flow cytometry. Multiple group comparisons were performed using ANOVA test (with Bonferroni correction). RESULTS: In individuals at risk of RA, longitudinal analysis showed that IRC frequencies increased just prior to onset of clinical synovitis, while naive T-cell frequencies reduced in those progressing to clinical synovitis, but increased in non-progressors. The use of naive/IRC data improved the accuracy of RA classification, especially in ACPA-negative patients. A distinct T-cell biomarker signature was observed in late-onset RA (>60 years old vs <59). In untreated RA, the predictive value of naive T-cell frequencies for methotrexate response was confirmed. For patients on methotrexate, naive T cells increased only between 6 and 12 months and only when in remission. IRC and Treg showed no consistent change. In patients treated with TNF inhibitors, naive T-cell frequency increased independently of response, whilst sustained IRC reductions and Treg increases were seen in remission. Once in stable clinical remission, only naive frequencies increased with the length of remission on conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs), whilst only Treg increased over time in TNF inhibitor-induced remission. CONCLUSION: These studies validated that T-cell subset measurements are independent from other currently used biomarkers, highlighting differences in the impact of drug modes of action on the three T-cell subsets. There is still an unmet need for biomarkers to predict response to TNF inhibition in early RA.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Anioke IC, Tastekin F, Alp G, et al. T-cell subset biomarkers across the rheumatoid arthritis disease continuum: from clinical utility to adoption in daily practice. Rheumatology (Oxford). 2026. PMID: 42271628. doi:10.1093/rheumatology/keag286

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。